title: [How I treat... refractory multiple myeloma with thalidomide].
abstract: Despite the use of high-dose chemotherapy with autologous hematopoietic stem cell transplantation, multiple myeloma remains largely uncurable. Indeed complete remission rate is about 50% and median survival reaches 5 years without plateau. Recently thalidomide has been identified as a promising agent. We report the clinical story of 2 patients with refractory myeloma that we treated successfully with thalidomide.
authors.affiliation: Université de Liège, Service d'Hématologie.
authors.forename: F
authors.initials: F
authors.lastname: Scerbo
authors.forename: G
authors.initials: G
authors.lastname: Matus
authors.forename: B
authors.initials: B
authors.lastname: Sautois
authors.forename: G
authors.initials: G
authors.lastname: Fillet
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001797:Blood Protein Electrophoresis; D001798:Blood Proteins / Q000032:analysis; D016207:Cytokines / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D012074:Remission Induction / Q000379:methods; D016019:Survival Analysis; D013792:Thalidomide / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D001798:Blood Proteins; D016207:Cytokines; D007166:Immunosuppressive Agents; D013792:Thalidomide
vernacular_title: Comment je traite ... le myélome multiple réfractaire par thalidomide.